Holmes Biopharma, Inc.: Financing and Year End Forecast
December 18 2007 - 9:00AM
Marketwired
SCOTTSDALE, ARIZONA announces that it has completed a
significant working capital financing. The Company can now continue
its fantastic growth in sales throughout 2008.
Holmes Biopharma's clinical research subsidiary, Qualia Clinical
Services Inc., will finish 2007 with sales of approximately $10
million. Management estimates that sales in 2008 will exceed $20
million, with clinics in Omaha, Nebraska, Toronto, Canada and Kiev,
Ukraine operating at full capacity.
Holmes Biopharma's strategy for 2008 includes entering the drug
development business with a significant acquisition targeted for
early in the new year.
About Holmes:
Holmes Biopharma, Inc. is a contract research organization
focused on providing integrated and cost effective clinical
development services to the pharmaceutical industry. Currently,
clinics operate in Omaha, Nebraska, USA, Toronto, Canada and Kiev,
Ukraine. For more information about the company please visit our
website at www.holmesbiopharma.com.
On behalf of the Board of Directors
John F. Metcalfe, President, CEO
Certain statements in this press release constitute "forward
looking statements" within the meaning of the United States
Securities Legislation. The Company's actual results could differ
from those in the forward-looking statements. Do not construe this
information as investment advice. This is not a solicitation to buy
or sell securities. This does not purport to be a complete analysis
of the Company. Investing in securities is speculative and carries
a high degree of risk. Past performance does not guarantee future
results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All
information contained in this press release should be independently
investigated. This press release contains forward-looking
statements. These remarks involve risks and uncertainties. Risks
are not limited to quarterly fluctuations in results or the
companies' management of growth and competition. Other risks are
detailed in the Company's SEC filings. Actual results may differ
materially from such information set forth herein.
Contacts: Holmes Biopharma, Inc. John Metcalfe 1-800-778-4990
Email: ir@holmesbiopharma.com Website: www.holmesbiopharma.com
Swiftsure (CE) (USOTC:HLMB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Swiftsure (CE) (USOTC:HLMB)
Historical Stock Chart
From Aug 2023 to Aug 2024